<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Biohaven Pharmaceutical Holding Co Ltd — News on 6ix</title>
<link>https://6ix.com/company/biohaven-pharmaceutical-holding-co-ltd</link>
<description>Latest news and press releases for Biohaven Pharmaceutical Holding Co Ltd on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 19 Mar 2026 11:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/biohaven-pharmaceutical-holding-co-ltd" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68354ceb78dffbe2df0e5b8d.webp</url>
<title>Biohaven Pharmaceutical Holding Co Ltd</title>
<link>https://6ix.com/company/biohaven-pharmaceutical-holding-co-ltd</link>
</image>
<item>
<title>Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment</title>
<link>https://6ix.com/company/biohaven-pharmaceutical-holding-co-ltd/news/biohavens-phase-2-obesity-study-with-taldefgrobep-alfa-a-novel-myostatin-activin-pathway-inhibitor-completes-enrollment</link>
<guid isPermaLink="true">https://6ix.com/company/biohaven-pharmaceutical-holding-co-ltd/news/biohavens-phase-2-obesity-study-with-taldefgrobep-alfa-a-novel-myostatin-activin-pathway-inhibitor-completes-enrollment</guid>
<pubDate>Thu, 19 Mar 2026 11:30:00 GMT</pubDate>
<description>Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today announced the completion of enrollment in a Phase 2 proof-of-concept (PoC) study with its myostatin-activin pathway inhibitor (MAPI), taldefgrobep alfa, which offers the potential to achieve high-quality weight loss in people living with obesity. Topline data fro</description>
</item>
<item>
<title>Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/biohaven-pharmaceutical-holding-co-ltd/news/biohaven-reports-recent-business-developments-and-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/biohaven-pharmaceutical-holding-co-ltd/news/biohaven-reports-recent-business-developments-and-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Mon, 02 Mar 2026 21:05:00 GMT</pubDate>
<description>Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a review of recent accomplishments and anticipated upcoming developments.</description>
</item>
<item>
<title>Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/biohaven-pharmaceutical-holding-co-ltd/news/biohaven-highlights-portfolio-progress-positive-161500989</link>
<guid isPermaLink="true">https://6ix.com/company/biohaven-pharmaceutical-holding-co-ltd/news/biohaven-highlights-portfolio-progress-positive-161500989</guid>
<pubDate>Mon, 12 Jan 2026 16:15:00 GMT</pubDate>
<description>Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today highlighted its broad portfolio progress at the 44th Annual J.P. Morgan Healthcare Conference. A copy of the slide presentation is available on the Events and Presentations section of the Biohaven website.</description>
</item>
<item>
<title>Biohaven to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026</title>
<link>https://6ix.com/company/biohaven-pharmaceutical-holding-co-ltd/news/biohaven-present-44th-annual-j-120000545</link>
<guid isPermaLink="true">https://6ix.com/company/biohaven-pharmaceutical-holding-co-ltd/news/biohaven-present-44th-annual-j-120000545</guid>
<pubDate>Wed, 07 Jan 2026 12:00:00 GMT</pubDate>
<description>Biohaven Ltd. (NYSE: BHVN) today announced that Vlad Coric, M.D., Chairman and Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference at The Westin St. Francis Hotel in San Francisco, California, on Monday, January 12, 2026, at 8:15 a.m. PST (11:15 a.m. EST).</description>
</item>
<item>
<title>Biohaven Provides Update From Phase 2 Proof-of-Concept Study with BHV-7000 in Major Depressive Disorder</title>
<link>https://6ix.com/company/biohaven-pharmaceutical-holding-co-ltd/news/biohaven-provides-phase-2-proof-180000897</link>
<guid isPermaLink="true">https://6ix.com/company/biohaven-pharmaceutical-holding-co-ltd/news/biohaven-provides-phase-2-proof-180000897</guid>
<pubDate>Wed, 24 Dec 2025 18:00:00 GMT</pubDate>
<description>Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today reported results from a Phase 2 proof-of-concept study evaluating BHV-7000 for the treatment of major depressive disorder (MDD). The study did not meet its primary endpoint, a reduction of depressive symptoms as measured by change in the Montgomery Åsberg Depress</description>
</item>
<item>
<title>Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress</title>
<link>https://6ix.com/company/biohaven-pharmaceutical-holding-co-ltd/news/biohaven-presents-clinical-safety-efficacy-120000337</link>
<guid isPermaLink="true">https://6ix.com/company/biohaven-pharmaceutical-holding-co-ltd/news/biohaven-presents-clinical-safety-efficacy-120000337</guid>
<pubDate>Thu, 11 Dec 2025 12:00:00 GMT</pubDate>
<description>Biohaven Ltd. (NYSE: BHVN) announced today that it presented clinical safety and efficacy data for BHV-1510 at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress, taking place from December 10-12, 2025, in London, United Kingdom. The presentation highlights Biohaven's novel next-generation trophoblast cell surface antigen 2 (Trop2) directed antibody drug conjugate (ADC), BHV-1510, in combination with Regeneron's anti-PD-1 cemiplimab demonstrating efficacy and manageab</description>
</item>
<item>
<title>Biohaven Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $200M</title>
<link>https://6ix.com/company/biohaven-pharmaceutical-holding-co-ltd/news/biohaven-announces-closing-upsized-public-210500816</link>
<guid isPermaLink="true">https://6ix.com/company/biohaven-pharmaceutical-holding-co-ltd/news/biohaven-announces-closing-upsized-public-210500816</guid>
<pubDate>Thu, 13 Nov 2025 21:05:00 GMT</pubDate>
<description>Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today announced the closing of its underwritten public offering of 26,833,334 of its common shares, which includes the full exercise of the underwriters' option to purchase 3,500,000 additional common shares, at a public offering prices of $7.50 per share. The offering was upsized t</description>
</item>
<item>
<title>Biohaven Announces Pricing of $175 Million Public Offering of Common Shares</title>
<link>https://6ix.com/company/biohaven-pharmaceutical-holding-co-ltd/news/biohaven-announces-pricing-175-million-121500141</link>
<guid isPermaLink="true">https://6ix.com/company/biohaven-pharmaceutical-holding-co-ltd/news/biohaven-announces-pricing-175-million-121500141</guid>
<pubDate>Wed, 12 Nov 2025 12:15:00 GMT</pubDate>
<description>Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today announced the pricing of its underwritten public offering of 23,333,334 of its common shares at a price to the public of $7.50 per share. In addition, Biohaven has granted the underwriters a 30-day option to purchase up to an additional 3,500,000 common shares at the public of</description>
</item>
<item>
<title>Biohaven Announces Proposed Public Offering of Common Shares</title>
<link>https://6ix.com/company/biohaven-pharmaceutical-holding-co-ltd/news/biohaven-announces-proposed-public-offering-210500644</link>
<guid isPermaLink="true">https://6ix.com/company/biohaven-pharmaceutical-holding-co-ltd/news/biohaven-announces-proposed-public-offering-210500644</guid>
<pubDate>Tue, 11 Nov 2025 21:05:00 GMT</pubDate>
<description>Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today announced that it has commenced an underwritten public offering of $150 million of its common shares. All of the common shares to be sold in the offering will be offered by Biohaven. In addition, Biohaven expects to grant the underwriters a 30-day option to purchase up to an a</description>
</item>
<item>
<title>Biohaven Reports Third Quarter 2025 Financial Results and Recent Business Developments</title>
<link>https://6ix.com/company/biohaven-pharmaceutical-holding-co-ltd/news/biohaven-reports-third-quarter-2025-115800001</link>
<guid isPermaLink="true">https://6ix.com/company/biohaven-pharmaceutical-holding-co-ltd/news/biohaven-reports-third-quarter-2025-115800001</guid>
<pubDate>Mon, 10 Nov 2025 11:58:00 GMT</pubDate>
<description>Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today reported financial results for the third quarter ended September 30, 2025, and provided a review of recent accomplishments and anticipated upcoming developments.</description>
</item>
<item>
<title>FDA Issues Complete Response Letter for Biohaven's VYGLXIA (troriluzole) New Drug Application for Spinocerebellar Ataxia</title>
<link>https://6ix.com/company/biohaven-pharmaceutical-holding-co-ltd/news/fda-issues-complete-response-letter-010600734</link>
<guid isPermaLink="true">https://6ix.com/company/biohaven-pharmaceutical-holding-co-ltd/news/fda-issues-complete-response-letter-010600734</guid>
<pubDate>Wed, 05 Nov 2025 01:06:00 GMT</pubDate>
<description>Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) seeking approval of VYGLXIA (troriluzole) for the treatment of spinocerebellar ataxia (SCA).</description>
</item>
<item>
<title>Biohaven Reports Second Quarter 2025 Financial Results and Recent Business Developments</title>
<link>https://6ix.com/company/biohaven-pharmaceutical-holding-co-ltd/news/biohaven-reports-second-quarter-2025-110000699</link>
<guid isPermaLink="true">https://6ix.com/company/biohaven-pharmaceutical-holding-co-ltd/news/biohaven-reports-second-quarter-2025-110000699</guid>
<pubDate>Mon, 11 Aug 2025 11:00:00 GMT</pubDate>
<description>Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today reported financial results for the second quarter ended June 30, 2025, and provided a review of recent accomplishments and anticipated upcoming developments.</description>
</item>
<item>
<title>Bexorg Announces Research Collaboration with Biohaven Leveraging Its Novel AI-Driven Whole-Brain Discovery Platform to Enhance CNS Drug Development</title>
<link>https://6ix.com/company/biohaven-pharmaceutical-holding-co-ltd/news/bexorg-announces-research-collaboration-with-biohaven-leveraging-its-novel-ai-driven-whole-brain-discovery-platform-to-enhance-cns-drug-development</link>
<guid isPermaLink="true">https://6ix.com/company/biohaven-pharmaceutical-holding-co-ltd/news/bexorg-announces-research-collaboration-with-biohaven-leveraging-its-novel-ai-driven-whole-brain-discovery-platform-to-enhance-cns-drug-development</guid>
<pubDate>Tue, 10 Jun 2025 18:00:00 GMT</pubDate>
<description>NEW HAVEN, Conn., June 10, 2025 (GLOBE NEWSWIRE) -- Bexorg, Inc., a pioneering techbio company working to decode the human brain and advance new therapies for central nervous system (CNS) disorders, today announced a multi-program research collaboration with Biohaven Ltd. (NYSE: BHVN) to identify, de-risk, and advance next-generation therapies for CNS disorders. As part of the collaboration, Bexorg’s novel whole-brain discovery platform will be used to demonstrate target engagement in relevant c</description>
</item>
<item>
<title>Biohaven Enrolls First Patient into Phase 2/3 Trial in Early Parkinson's Disease, Targeting Neuroinflammation with Novel Brain-Penetrant TYK2/JAK1 Inhibitor</title>
<link>https://6ix.com/company/biohaven-pharmaceutical-holding-co-ltd/news/biohaven-enrolls-first-patient-phase-110100969</link>
<guid isPermaLink="true">https://6ix.com/company/biohaven-pharmaceutical-holding-co-ltd/news/biohaven-enrolls-first-patient-phase-110100969</guid>
<pubDate>Thu, 29 May 2025 11:01:00 GMT</pubDate>
<description>Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing therapies to treat a broad range of rare and common diseases, announced today that it has initiated a global Phase 2/3 study of the first-in-clinic, orally-administered, brain-penetrant, and highly selective TYK2/JAK1 inhibitor, BHV-8000, for the treatment of early Parkinson's disease (PD).</description>
</item>
<item>
<title>Biohaven Highlights Innovation and Advancement Across MoDE and TRAP Degrader Platform at R&D Day, Announcing Positive TRAP Degrader Data Achieving > 80% Sustained Reductions in Galactose-Deficient IgA1 (Gd-IgA1) with Potential First-in-Class BHV-1400 for IgA Nephropathy (IgAN)</title>
<link>https://6ix.com/company/biohaven-pharmaceutical-holding-co-ltd/news/biohaven-highlights-innovation-advancement-across-190000873</link>
<guid isPermaLink="true">https://6ix.com/company/biohaven-pharmaceutical-holding-co-ltd/news/biohaven-highlights-innovation-advancement-across-190000873</guid>
<pubDate>Wed, 28 May 2025 19:00:00 GMT</pubDate>
<description>Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today highlighted the success of its first MoDE™ and TRAP™ degraders in achieving key target pharmacodynamic endpoints and announced plans to initiate pivotal trials in Graves' Disease and in IgA nephropathy in 2H 2025 and 1H 2026, respectively at Biohaven's 2025 R&D Da</description>
</item>
<item>
<title>Biohaven Presents Oncology Program Updates and Preliminary Clinical Data Showcasing Innovative Trop2 and FGFR3 Antibody Drug Conjugates (ADCs) Incorporating Novel TopoIx Payload with Potential to Treat a Wide Variety of Tumors</title>
<link>https://6ix.com/company/biohaven-pharmaceutical-holding-co-ltd/news/biohaven-presents-oncology-program-updates-113000569</link>
<guid isPermaLink="true">https://6ix.com/company/biohaven-pharmaceutical-holding-co-ltd/news/biohaven-presents-oncology-program-updates-113000569</guid>
<pubDate>Wed, 28 May 2025 11:30:00 GMT</pubDate>
<description>Biohaven Ltd. (NYSE: BHVN) (Biohaven), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today provided an update and preliminary clinical data from its oncology development programs at Biohaven's 2025 R&D Day, held concurrently with the Yale Innovation Summit in New Haven, Connecticut. The presentation slides from Biohaven's R&D day for Oncology and its othe</description>
</item>
<item>
<title>FDA Extends PDUFA Date of Biohaven's Troriluzole NDA for Rare Disease Spinocerebellar Ataxia</title>
<link>https://6ix.com/company/biohaven-pharmaceutical-holding-co-ltd/news/fda-extends-pdufa-date-biohavens-224300461</link>
<guid isPermaLink="true">https://6ix.com/company/biohaven-pharmaceutical-holding-co-ltd/news/fda-extends-pdufa-date-biohavens-224300461</guid>
<pubDate>Wed, 14 May 2025 22:43:00 GMT</pubDate>
<description>Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), today announced that the Division of Neurology 1 within FDA's Office of Neuroscience informed the Company that they are extending the PDUFA date for the troriluzole new drug application (NDA) for the treatment of spinocerebellar ataxia (SCA) by three months to provide time for a full review of Biohaven's recent submissions related to information requests from the FDA. The Division also informed Biohaven that it is currently planning to hold a</description>
</item>
<item>
<title>Biohaven Reports First Quarter 2025 Financial Results and Recent Business Developments</title>
<link>https://6ix.com/company/biohaven-pharmaceutical-holding-co-ltd/news/biohaven-reports-first-quarter-2025-200500727</link>
<guid isPermaLink="true">https://6ix.com/company/biohaven-pharmaceutical-holding-co-ltd/news/biohaven-reports-first-quarter-2025-200500727</guid>
<pubDate>Mon, 12 May 2025 20:05:00 GMT</pubDate>
<description>Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today reported financial results for the first quarter ended March 31, 2025, and provided a review of recent accomplishments and anticipated upcoming developments.</description>
</item>
<item>
<title>Biohaven Announces Investment up to $600 Million by Oberland Capital</title>
<link>https://6ix.com/company/biohaven-pharmaceutical-holding-co-ltd/news/biohaven-announces-investment-600-million-113000430</link>
<guid isPermaLink="true">https://6ix.com/company/biohaven-pharmaceutical-holding-co-ltd/news/biohaven-announces-investment-600-million-113000430</guid>
<pubDate>Mon, 28 Apr 2025 11:30:00 GMT</pubDate>
<description>Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today announced that it has entered into an agreement with Oberland Capital Management LLC (Oberland Capital) for an investment of up to $600 million in the Company, with the first tranche of $250 million of gross proceeds to be funded at closing on or befo</description>
</item>
<item>
<title>Biohaven Presents Data Across Innovative Neuroscience Portfolio at the 2025 American Academy of Neurology (AAN) Annual Meeting</title>
<link>https://6ix.com/company/biohaven-pharmaceutical-holding-co-ltd/news/biohaven-presents-data-across-innovative-130000816</link>
<guid isPermaLink="true">https://6ix.com/company/biohaven-pharmaceutical-holding-co-ltd/news/biohaven-presents-data-across-innovative-130000816</guid>
<pubDate>Sat, 05 Apr 2025 13:00:00 GMT</pubDate>
<description>Biohaven Ltd. (NYSE: BHVN) announced today that it will present 13 abstracts at the 2025 American Academy of Neurology (AAN) Annual Meeting, taking place from April 5 to April 9, 2025 in San Diego, California. The presentations highlight Biohaven's innovative neuroscience pipeline across multiple early and late-stage development programs including Kv7 ion channel modulation, extracellular protein degradation, TRPM3 antagonism, TYK2/JAK1 inhibition, and glutamate modulation.</description>
</item>
</channel>
</rss>